Sleep Disorders

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the sleep disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 19, 2024.

An analysis of a phase 3 trial of low sodium oxybate in patients with idiopathic hypersomnia identified a minimal clinically important difference in the visual analog scale for sleep inertia.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the American Academy of Neurology Annual Meeting.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending April 12, 2024.

ALKS 2680, an investigational orexin 2 receptor agonist, showed promise for improving sleep latency in patients with narcolepsy type 2 and idiopathic hypersomnia in a phase 1b study.

The newly initiated phase 3 trial follows a successful phase 2 study where treatment with pitolisant resulted in greater improvement on the Epworth Sleepiness Scale for Children and Adolescents than placebo.

Here's some of what is coming soon to NeurologyLive® this week.

The presence of a sleep disorder was associated with a nearly 2-fold increase in the risk of increased health care utilization, with specific odds associated with individual sleep disorders.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on limb girdle muscular dystrophy.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending Aprl 5, 2024.

The medical director of the Center for Sleep Medicine at Weill Cornell Medicine talked about the importance of sleep health in modern life with the increasing prevalence of sleep disorders such as narcolepsy in the United States. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is multiple sclerosis and MS mimics.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 29, 2024.

Sleeping Around the Podcast is joined by Rachel Nesmith, a patient with narcolepsy, who shares her story of overcoming the burdens and impairments of living with narcolepsy and cataplexy.

Grace Griesbach, PhD, the national director of clinical research for Centre for Neuro Skills, discussed the impact of REM sleep on memory following traumatic brain injury and the importance of considering sex as a biological variable.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is movement disorders and multiple system atrophy.

Transgender and gender-diverse patients have unique neurological considerations, but often, neurologists are unaware of the needs that are specific to this community.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 22, 2024.

This complex waste clearance pathway within the CNS plays a crucial role in maintaining brain homeostasis, as a mechanism of protein waste removal alongside autophagy and protein aggregate ubiquitination.

Join us on April 8 on our LinkedIn and X pages for our #PreAANChat premeeting social chat ahead of the 2024 American Academy of Neurology Annual Meeting!

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Neurology News Network for the week ending March 16, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 15, 2024.

A meta-analysis on studies assessing FDA-approved dual orexin receptor antagonists for insomnia treatment highlighted a greater risk of adverse events, particularly for narcolepsy-like symptoms.

In recent news, the FDA has issued a complete response letter for Vanda Pharmaceuticals' tasimelteon for treating insomnia because of identified deficiencies and cannot be approved in its current form.